Cleo Diagnostics (ASX:COV) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cleo Diagnostics's Net Income for the six months ended in Dec. 2023 was A$-2.61 Mil. Cleo Diagnostics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Cleo Diagnostics's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Cleo Diagnostics's Net Margin % or its related term are showing as below:

ASX:COV's Net Margin % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: -1.34
* Ranked among companies with meaningful Net Margin % only.

Cleo Diagnostics Net Margin % Historical Data

The historical data trend for Cleo Diagnostics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Net Margin % Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Net Margin %

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Net Margin %	-	-	-

Competitive Comparison of Cleo Diagnostics's Net Margin %

For the Medical Devices subindustry, Cleo Diagnostics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Net Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Net Margin % falls into.

Cleo Diagnostics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cleo Diagnostics's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-1.73	/	0
	=	%

Cleo Diagnostics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.611	/	0
	=	%

Cleo Diagnostics (ASX:COV) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cleo Diagnostics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines